Lifestyle

SHED ALERT

GLP-1 Jabs Linked to Rare Side Effect That’s Worse Than ‘Ozempic Face’

This front-and-center side effect might hit even harder than cramping, pain, and a bit of loose skin.

Tamilore OshikanluContributor

PublishedJul 23, 2026, 6:10 PM EDT

UpdatedJul 23, 2026, 6:10 PM EDT

Updated Jul 23, 2026, 6:10 PM EDTPublished Jul 23, 2026, 6:10 PM EDT

Comments

Blockbuster weight-loss drugs are being linked to a rare but upsetting side effect that’s showing up in the shower drain.

As the popularity of GLP-1 medications for type 2 diabetes and obesity continues to skyrocket, patients and doctors report a growing list of side effects. Some are common, such as vomiting, bloating, cramping, and loose skin, colloquially known as “Ozempic face.” Others are rare, including “Ozempic feet,” mood changes, and even scurvy.

Still, even with all the potential side effects, more people than ever are being prescribed semaglutide and tirzepatide. But new research on a rare yet devastating side effect may deter some prospective GLP-1 seekers: hair loss.

A study by researchers at the University of Pennsylvania found that people taking GLP-1 medications such as Ozempic, Wegovy, and Mounjaro faced a higher risk of developing alopecia than patients taking two other classes of diabetes drugs.

JUST EAR ME OUT

Ozempic Users Say This Tiny Side Effect Drives Them Nuts

Roosa Rahkonen

The study, published Wednesday in The BMJ, a globally respected peer-reviewed British medical journal, followed patients for an average of 2.7 years and found that the increased risk was concentrated in non-scarring alopecia—a type of hair loss that does not permanently destroy the follicles.

After at least two years of treatment, GLP-1 users had a 37 percent higher chance of developing alopecia than patients taking SGLT-2 drugs and 68 percent higher odds than those taking DPP-4 drugs, both of which are also used to treat type 2 diabetes.

The actual risk, however, remained low.

Researchers recorded approximately three to nine cases of alopecia for every 1,000 patients each year. That translates to roughly seven GLP-1 users developing hair loss, compared with five SGLT-2 users and four DPP-4 users annually.

The findings may sound familiar to those who follow news about GLP-1s.

Comedian and influencer Claudia Oshry revealed in 2024 that her hair began “shedding” after she lost 70 pounds while taking Ozempic.

“It didn’t thin, but it started SHEDDING—which is literally worse,” the 31-year-old said during an Instagram Q&A. She added that it took six to nine months for her hair to “get back to normal.”

Buying Beverly Hills star Sophia Umansky, the 26-year-old daughter of The Real Housewives of Beverly Hills star Kyle Richards, also documented “dramatic” hair loss after taking Mounjaro.

DANGEROUS DOSE

Doctors Sound the Alarm on Rising GLP-1 Overdoses

Tamilore Oshikanlu

In an April 2025 TikTok, Umansky showed viewers the clumps of hair she had collected in her bathroom and joked that she would be “bald” within a week.

Umansky did not blame Mounjaro itself. She suspected that rapid weight loss and not consuming enough protein and vitamins had triggered the shedding.

Scientists are still trying to determine why some GLP-1 users lose hair.

According to the study’s researchers, rapid weight loss can disrupt the hair’s normal growth cycle and trigger telogen effluvium, a common and generally temporary form of shedding.

Changes in eating habits may also leave patients deficient in nutrients such as iron and zinc, which can further interfere with hair growth, according to the National Library of Medicine.

The medical records did not show how severe the patients’ hair loss was, how long it lasted, or whether their hair eventually grew back.

Play Video

Other research suggests that weight loss alone may not fully explain the shedding.

A study published in the Journal of the American Academy of Dermatology compared more than 1 million GLP-1 users with patients taking metformin, a common diabetes drug that is not associated with the same dramatic weight loss.

The researchers found increased risk of several forms of alopecia among those taking GLP-1 medications.

IF THE SHOE FITS

GLP-1 Users Say Bizarre Side Effect Is Hard to Ignore

Tamilore Oshikanlu

Another study compared 11,046 tirzepatide users with the same number of semaglutide users. Hair loss was recorded in 4.24 percent of patients taking tirzepatide—the ingredient in Mounjaro and Zepbound—compared with 3.33 percent taking semaglutide, which is sold as Ozempic and Wegovy.

Researchers emphasized that hair loss rarely causes physical harm but can still take an emotional toll, the degree of which is highly personal.

“Hair loss is a patient-valued outcome,” lead researcher Yong Chen wrote, adding that it can affect “self-esteem, quality of life, and adherence to treatment.”

For many, the benefits vastly outweigh the drawbacks, but researchers said the findings should help patients understand the potential trade-offs before starting—or deciding whether to continue—the highly popular medication.

Tamilore OshikanluContributor

Got a tip? Send it to The Daily Beast.